According to a new report published by Allied Market Research, titled,"Cephalosporin Market by Generation, Type, Route of Drug Administration, and Application: Global Opportunity Analysis and Industry Forecast, 2018 - 2025,"the global cephalosporin market size was valued at $11,869 million in 2017, and is estimated to reach $14,022 million by 2025, growing at a CAGR of 2.0% from 2018 to 2025. The third-generation cephalosporin segment held more than 30% of the total cephalosporin market share in 2017.
Cephalosporin is a group of semisynthetic, broad-spectrum antibiotics, which is majorly used to treat bacterial infections. The major factors contributing to the growth of the market include increase in incidence of population suffering from pneumonia, tonsillitis, bronchitis, and gonorrhea. In addition, increase in R&D activities to develop highly efficient & safe drugs and upsurge in use of combination therapies further boost the market growth. However, side effects associated with cephalosporin and development of drug-resistant bacterial strains restrain the market growth.
Based on application, the market is segmented into respiratory tract infection, skin infection, ear infection, urinary tract infection, sexually transmitted infection, and others. The respiratory tract infection segment generated the highest revenue in 2017 and is anticipated to maintain its dominance throughout the forecast period, as cephalosporin are used for treatment of both upper & lower respiratory tract infection and lower respiratory infections are the leading infectious causes of death globally. Hence, oral cephalosporin is used in the treatment of lower and upper respiratory tract infections widely. However, the sexually transmitted infection is expected to register highest CAGR during the forecast period, due to the rising rate of sexually transmitted infections globally and some second-generation cephalosporin and most of the third-generation cephalosporin are effective in the treatment.
Based on generation, the market is classified into first-generation cephalosporin, second-generation cephalosporin, third-generation cephalosporin, fourth-generation cephalosporin, and fifth-generation cephalosporin. The third-generation cephalosporin segment generated the highest revenue in 2017 and is anticipated to maintain its dominance throughout the forecast period, as these have a broader spectrum of activity and these are used for the treatment of Gram-negative bacillary meningitis, serious infections of enterobacteriaceae, otitis media, and others. However, the fifth-generation cephalosporin is expected to register highest CAGR of 3.3% during the forecast period.
Based on region, the antibiotics market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Asia-Pacific dominated the market in 2017, accounting for the highest share, and is anticipated to maintain cephalosporin market trends throughout the forecast period. This is attributed to increased consumption of cephalosporin, its easy availability, and rise in sale of over-the-counter drugs, and increase in bacterial infection in the region. LAMEA is projected to register the highest CAGR of 4.2% during the forecast period, owing to increase in incidence of infectious diseases. In addition, rise in healthcare expenditure is anticipated to offer a lucrative opportunity for the market growth.
Key Findings of the Cephalosporin Market:
- Branded cephalosporin segment is expected to register the highest CAGR of 2.3% during the analysis period.
- Based on route of drug administration, the injectable cephalosporin segment accounted for the largest share in 2017 and is expected to maintain its dominance during the forecast period.
- India and China collectively contributed for more than 40% share of the Asia-Pacific cephalosporin market in 2017.
- U.S. was the major shareholder that accounted for more than 90% of the North America cephalosporin market in 2017.
The report provides a comprehensive analysis of the key players operating in the global cephalosporin industry, Allergan Plc., Bristol-Myers Squibb Company, F.Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Lupin Limited (Lupin Pharmaceuticals, Inc.), Merck & Co. Inc., Novartis International AG, Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd. The other players in the value chain include Eli Lilly and Company, Bayer HealthCare, Sun Pharmaceutical, Shionogi, and others.